The UK has left the EU, and the transition period after Brexit comes to an end this year. From 1 January 2021, the UK would no longer be part of the EU medicines and medical devices regulatory networks.
Submissions related to human medicines would need to be submitted directly to the British Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA is currently making preparations to ensure that companies can continue to submit regulatory and notification information to the UK. In this framework several webinars have been made available.